Trial Profile
Open, primary vaccination study to assess safety and reactogenicity of GSK [GlaxoSmithKline] biologicals' DTPa/Hib vaccine when administered to healthy Chinese infants at 3, 4 and 5 months of age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Hib-DTaP vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 15 May 2007 New trial record.